Treatment of Central Precocious Puberty with an LHRH Agonist (Buserelin): Effect on Growth and Bone Maturation after Three Years of Treatment
- 1 January 1987
- journal article
- Published by S. Karger AG in Hormone Research
- Vol. 28 (2-4) , 149-154
- https://doi.org/10.1159/000180938
Abstract
The LHRH analog Buserelin was used to treat 27 children (21 girls, 6 boys) with central precocious puberty. Nineteen patients had idiopathic precocious puberty and 8 had organic lesions (hamartoma, hydrocephalus or suprasellar arachnoid cyst). All patients received 20 or 30 µg/kg/day s.c. of Buserelin, and we obtained plasma E2 < 20 pg/ml, vaginal maturation index < 30 in girls or plasma testosterone < 0.3 ng/ml in boys. The mean growth rate decreased from 9.3 ± 0.5 to 4.6 ± 1.3 cm/year after 3 years. The velocity of skeletal maturation decreased so that the final height prediction improved by a mean value of 1.6 SD. As the follow-up increases, this study confirms that LHRHa therapy is effective and potentially improves the final height of children presenting active and severe central precocious puberty.Keywords
This publication has 0 references indexed in Scilit: